Peptide Therapeutics Industry Overview

The global peptide therapeutics market size is expected to reach USD 66.41 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to grow at a CAGR of 6.1% from 2024 to 2030. Increasing demand for efficient and rapid-acting therapeutics for the treatment of cancer and other lifestyle-associated disorders, which result in lesser adverse effects, is anticipated to propel market growth. The rising incidence of cancer calls for exploring and introducing other means of therapies and low-cost treatment alternatives is expected to drive the market. Moreover, the growing geriatric population is expected to widen the consumer base by triggering the incidence rate of target diseases such as cancer and diabetes, which is expected to drive the demand for peptide therapeutics.

As per the International Agency for Research on Cancer (GLOBOCAN 2020) report, there will be 19,292,789 new cancer cases diagnosed globally in 2020, with 9,958,133 cancer deaths. Furthermore, the five-year prevalence of cancer was projected to be 50,550,287 worldwide. The global number of new cases of cancer is projected to reach 28,887,940 by 2040. As a result, the higher incidence of cancers around the world is set to perform an important role in the development of peptide therapeutics over the forecast period. Besides that, increasing awareness among health care providers and patients about the negative effects of chemotherapy and/or radiation therapy is a primary factor influencing the increased emphasis on alternative therapeutics like peptide-based drugs.

Gather more insights about the market drivers, restrains and growth of the Peptide Therapeutics Market

Technological advancements in the peptide manufacturing process are driving the market during the forecast period. Manufacturers and suppliers are focusing on the adoption of novel technologies to manufacture efficient drug molecules with low time and capital investment. Improvement in purification and automation process and less generation of waste are additional factors contributing to the market growth. For instance, in March 2022, Amgen announced the official opening of its latest bio-manufacturing facility in Holly Springs, North Carolina. The facility, which is set to open in 2025, will help cope with the growth of Amgen's medicines, which treat serious diseases like cancer and heart disease.

The COVID-19 pandemic is anticipated to spur the spectrum of cancer care, which includes delayed diagnoses, therapeutic interventions, and the impeding of clinical trials focused on developing cost-effective therapeutics for cancer treatment, with peptide therapeutics for cancer treatment being no exception, as per a research article published in Nature Cancer, 2020. There have been 21 peptide drugs in therapies for the treatment of COVID-19 as of May 2020, such as 15 synthetic peptides for the therapies of acute respiratory distress syndrome (ARDS) as well as other respiratory illnesses induced by severe acute respiratory infection. However, current implementations of peptide therapeutics in oncological and metabolic disorders and other fields have been hampered by drug shortages, operational problems, and the slow progress of clinical trials involving non-COVID-19 therapeutics.

For instance, in May 2022, EVER Pharma announced that Bortezomib has received EU-wide approval for the treatment of individuals with symptomatic myeloma and mantle cell lymphoma1. In May 2022, The European Commission approved Novartis' Jakavi post-steroid therapy for acute and chronic graft-versus-host ailments. Jakavi will be the first JAK1/2 inhibitor widely available for patients in Europe with steroid-refractory graft-versus-host ailment. In September 2021, Nimble Therapeutics and Incyte entered into strategic collaborative research to discover additional new peptide therapies.

Browse through Grand View Research's Pharmaceuticals Industry Research Reports.

• The global nutritional supplements market size was estimated at USD 485.62 billion in 2024 and is expected to grow at a CAGR of 6.42% from 2025 to 2030.
  
  
• The global metabolic disorder therapeutics market size was estimated at USD 77.24 billion in 2024 and is projected to grow at a CAGR of 7.8% from 2025 to 2030. 

Peptide Therapeutics Market Segmentation

Grand View Research has segmented the global peptide therapeutics market report based on application, type, type of manufacturer, route of administration, synthesis technology, and region

Peptide Therapeutics Application Outlook (Revenue, USD Billion, 2018 - 2030)

• Cancer
• Metabolic Disorders
• Cardiovascular Disorders
• Respiratory Disorders
• Gastrointestinal Disorders
• Infectious Diseases
• Pain
• Dermatological Disorders
• Neurological Disorders
• Renal Disorders
• Others

Peptide Therapeutics Type Outlook (Revenue, USD Billion, 2018 - 2030)

• Generic
• Innovative

Peptide Therapeutics Type of Manufacturers Outlook (Revenue, USD Billion, 2018 - 2030)

• In-house
• Outsourced

Peptide Therapeutics Route of Administration Outlook (Revenue, USD Billion, 2018 - 2030)

• Parenteral Route
• Oral Route
• Pulmonary
• Mucosal
• Others

Peptide Therapeutics Synthesis Technology Outlook (Revenue, USD Billion, 2018 - 2030)

• Solid Phase Peptide Synthesis (SPPS)
• Liquid Phase Peptide Synthesis (LPPS)
• Hybrid Technology

Peptide Therapeutics Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America
  • US
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• MEA
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait

Key Companies profiled:

• Eli Lilly and Company
• Pfizer Inc.
• Amgen Inc.
• Takeda Pharmaceutical Company Limited
• AstraZeneca
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Hoffmann-La Roche Ltd
• Novartis AG
• Novo Nordisk A/S
• GlaxoSmithKline plc.
• Ironwood Pharmaceuticals, Inc.
• Radius Health, Inc.
• Ipsen Pharma

Key Peptide Therapeutics Company Insights

New product development and technological advancements are key strategies undertaken by major players to gain market position. Moreover, increasing collaborations for undertaking trials of new drugs are estimated to increase competitive rivalry.

• In March 2023, Ono Pharmaceuticals and PeptiDream entered into a collaboration for drug discovery and development of Macrocyclic Constrained Peptide Therapeutics
• In October 2023, Biosynth acquired Pepceuticals Limited, a British synthetic peptide manufacturer, and through this acquisition company aimed to strengthen its peptide division

Order a free sample PDF of the Peptide Therapeutics Market Intelligence Study, published by Grand View Research.